Incidence and severity of ICANS following CAR-T therapy in patients previously receiving ifosfamide

Bone Marrow Transplant. 2023 Feb;58(2):219-221. doi: 10.1038/s41409-022-01873-6. Epub 2022 Nov 14.

Authors

Hunter Sowell¹, Katie Gatwood², Matthew Perciavalle²

Affiliations

¹ Department of Pharmacy, Vanderbilt University Medical Center, Nashville, TN, USA. [email protected].
² Department of Pharmacy, Vanderbilt University Medical Center, Nashville, TN, USA.

PMID: 36376471
DOI: 10.1038/s41409-022-01873-6

No abstract available

Publication types

Letter

MeSH terms

Humans
Ifosfamide / adverse effects
Immunotherapy, Adoptive
Incidence
Neurotoxicity Syndromes*
Patients
Receptors, Chimeric Antigen*

Substances

Ifosfamide
Receptors, Chimeric Antigen